TIM
ACET icon

Thompson Investment Management’s Adicet Bio ACET Stock Holding History

Thompson Investment Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$60 – 490
2025
Q1 		$60 Hold
5
– – ﹤0.01% 478
2024
Q4 		$77 Hold
5
– – ﹤0.01% 491
2024
Q3 		$115 Hold
5
– – ﹤0.01% 490
2024
Q2 		$97 Hold
5
– – ﹤0.01% 490
2024
Q1 		$188 Hold
5
– – ﹤0.01% 501
2023
Q4 		$151 Hold
5
– – ﹤0.01% 413
2023
Q3 		$110 Hold
5
– – ﹤0.01% 399
2023
Q2 		$194 Hold
5
– – ﹤0.01% 400
2023
Q1 		$461 Buy
+5
New +$627 ﹤0.01% 389

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Thompson Investment Management's ACET Position: Q2 2025 in Review

Thompson Investment Management sold out of Adicet Bio (ACET) in Q2 2025, closing a stake of 5 shares — an estimated $60 sold.

Thompson Investment Management first reported a position in ACET in Q1 2023 and held it in 9 quarters. The position peaked at $461 in Q1 2023. 49 funds tracked by Wall St. Rank hold ACET as of Q2 2025.

  • Thompson Investment Management reported no remaining Adicet Bio position as of Q2 2025 after selling out during the quarter.
  • Thompson Investment Management sold 5 Adicet Bio shares in Q2 2025, an estimated $60.
  • Thompson Investment Management first reported a position in Adicet Bio in Q1 2023 and held it in 9 quarters.
  • Thompson Investment Management's Adicet Bio position peaked at $461 in Q1 2023.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2025.

Based on Thompson Investment Management's 13F filing for Q2 2025, filed 24 Jul 2025.